Showing 4011-4020 of 9772 results for "".
- ICONIC-LEAD: Oral Icotrokinra Clears Skin in 75% of Adolescents with Plaque Psoriasishttps://practicaldermatology.com/news/oral-icotrokinra-clears-skin-in-75-of-adolescents-with-plaque-psoriasis/2474078/Icotrokinra, an investigational oral IL-23 receptor antagonist, led to completely clear skin in 75% of adolescents with moderate-to-severe plaque psoriasis by week 24, according to results presented at the 2025 World Congress of Pediatric Dermatology.
- riSCC App Launched for Risk Stratification of cSCChttps://practicaldermatology.com/news/riSCC-App-Launched-Risk-Stratification-cSCC/2471817/The not-for-profit organization Skin Cancer Consortium Outcomes (SCOUT) announced it has launched riSCC, a data-driven clinician mobile app designed for risk stratification of cutaneous squamous cell carcinoma (cSCC) in clinical settings. SCOUT, founded in 2018, is committed to transformi
- Lipid Metabolites Linked to Atopic Dermatitis Riskhttps://practicaldermatology.com/news/lipid-metabolites-linked-to-atopic-dermatitis-risk/2471714/A two-sample Mendelian randomization (TSMR) study has identified 13 lipid-related metabolite traits that influence the risk of developing atopic dermatitis (AD). Researchers examined genome-wide association study (GWAS) datase
- Study: 60% Lesion Clearance in Actinic Keratosis Patients Using Topical Bimiralisib Gelhttps://practicaldermatology.com/news/study-60-lesion-clearance-in-actinic-keratosis-patients-using-topical-bimiralisib-gel/2471542/Newly presented interim results from a phase 2 clinical trial evaluating bimiralisib topical gel (2%) saw more than half of patients with actinic keratosis achieving complete or partial lesion clearance. Bimiralisib, a pan-PI3
- Lebrikizumab Achieves Deep and Sustained Response at 3 Years in ADhttps://practicaldermatology.com/news/Lebrikizuab-Achieves-Deep-Sustained-Response-3-Years-AD/2471538/Lebrikizumab (EBGLYSS) achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis (eczema) at 3 years in the ADjoin long-term extension study presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, Eli Lilly and Company anno
- Analysis Finds 'Substantial' Links Between Nail PsO Lesions and Locationshttps://practicaldermatology.com/news/Analysis-Finds-Substantial-Links-Between-Nail-PsO-Lesions-Locations/2471103/A spatial relationship between onycholysis and oil spots, with the intra-nail location of onycholysis being more distal compared to the nearest oil spots, was one of the primary observations in a new analysis of nail psoriasis published in Annals of Dermatology. “Analysis of the Intra-Nail
- Practical Dermatology Names Dr. Lisa Swanson Associate Medical Editorhttps://practicaldermatology.com/news/practical-dermatology-names-dr-lisa-swanson-associate-medical-editor/2470863/Elizabeth (Lisa) Swanson, MD, FAAD, has accepted the position of Associate Medical Editor of Practical Dermatology, the journal announced. In this capacity, Dr. Swanson will work closely with Chief Medical Editor Neal Bhatia, MD, FAAD, to provide direction for Practical Dermat
- Study: Dual-Action Topical Treatment Reduces Lesion Counts in Adult Acne Patientshttps://practicaldermatology.com/news/study-dual-action-topical-treatment-reduces-lesion-counts-adult-acne-patients/2470855/Results from a recent pilot study suggested that a combination therapy of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel with clascoterone 1% cream was effective in reducing lesions in adult acne patients. Researchers for the study enrolled 20 adult participants with
- Castle Biosciences' Test Identifies AD Patients Likely to Achieve EASI90https://practicaldermatology.com/news/castle-biosciences-test-identifies-ad-patients-likely-achieve-easi90/2470795/Castle Biosciences has announced its investigational gene expression profile test for atopic dermatitis (AD) may identify patients likely to achieve a 90% or greater reduction in Eczema Area and Severity Index (EASI) scores within three months of targeted therapy initiation. Currently, ov
- Study Explores How Moderate to Severe Hand Eczema Affects Quality of Lifehttps://practicaldermatology.com/news/moderate-severe-hand-eczema-quality-life-challenges-explored/2470762/Even mild hand eczema can significantly impair one's quality of life and mental health, according to a new study. The findings, presented at the recent Revolutionizing Atopic Dermatitis (RAD) Conference, spanned data collected from 2013 to 2020, addressed the outsized impact of hand eczem